发布求助
文献互助 智能选刊 最新文献

Poster Presentations - Proffered Abstracts最新文献

筛选
英文 中文
Abstract P241: A highly potent HPK1 inhibitor augments immune cell activation and anti-tumor immunity in a syngeneic tumor mouse model P241:一种高效的HPK1抑制剂在同基因肿瘤小鼠模型中增强免疫细胞激活和抗肿瘤免疫
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p241
Hao Liu, Lei Wu, Song Feng, Wei Huang, Huijuan Li, Jing Lin, Yangyang Liu, L. Mei, B. Ren, Julie Xie, L. Yao, W. Zhong
{"title":"Abstract P241: A highly potent HPK1 inhibitor augments immune cell activation and anti-tumor immunity in a syngeneic tumor mouse model","authors":"Hao Liu, Lei Wu, Song Feng, Wei Huang, Huijuan Li, Jing Lin, Yangyang Liu, L. Mei, B. Ren, Julie Xie, L. Yao, W. Zhong","doi":"10.1158/1535-7163.targ-21-p241","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p241","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89424444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P139: An estrogen receptor beta agonist liquiritigenin potentiates inhibition of hormone-dependent breast-cancer growth by cholesterol biosynthesis inhibitor RO 48-8071 摘要:雌激素受体激动剂利尿原素增强了胆固醇生物合成抑制剂RO 48-8071对激素依赖性乳腺癌生长的抑制作用
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p139
Yayun Liang, S. Hyder
{"title":"Abstract P139: An estrogen receptor beta agonist liquiritigenin potentiates inhibition of hormone-dependent breast-cancer growth by cholesterol biosynthesis inhibitor RO 48-8071","authors":"Yayun Liang, S. Hyder","doi":"10.1158/1535-7163.targ-21-p139","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p139","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87364634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P186: Preclinical evaluation of the proteasome inhibitor ixazomib (MLN2238) on nasopharyngeal cacinoma (NPC) P186:蛋白酶体抑制剂ixazomib (MLN2238)治疗鼻咽癌(NPC)的临床前评价
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p186
K. Li, V. Lee, G. Tsao
{"title":"Abstract P186: Preclinical evaluation of the proteasome inhibitor ixazomib (MLN2238) on nasopharyngeal cacinoma (NPC)","authors":"K. Li, V. Lee, G. Tsao","doi":"10.1158/1535-7163.targ-21-p186","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p186","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85470167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P083: Metastatic NSCLC -Re-challenging with first generation TKI after a drug free holiday after resistance to 3rd generation TKI P083:转移性NSCLC -在对第三代TKI耐药后无药期后再次挑战第一代TKI
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p083
Surya Acharya
{"title":"Abstract P083: Metastatic NSCLC -Re-challenging with first generation TKI after a drug free holiday after resistance to 3rd generation TKI","authors":"Surya Acharya","doi":"10.1158/1535-7163.targ-21-p083","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p083","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82290387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P121: Dual RAF/MEK inhibitor VS-6766 for treatment of solid tumors with diverse MAPK pathway alterations P121:双RAF/MEK抑制剂VS-6766治疗多种MAPK通路改变的实体肿瘤
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p121
S. Coma, S. Chowdhury, M. Musteanu, M. Barbacid, J. Pachter
{"title":"Abstract P121: Dual RAF/MEK inhibitor VS-6766 for treatment of solid tumors with diverse MAPK pathway alterations","authors":"S. Coma, S. Chowdhury, M. Musteanu, M. Barbacid, J. Pachter","doi":"10.1158/1535-7163.targ-21-p121","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p121","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90235739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P095: Isogenic CRISPR anchor screens identified actionable nodes to CHK1/2 inhibitor prexasertib in TP53 mutant cancer P095:等基因CRISPR锚定筛选在TP53突变型癌症中鉴定出CHK1/2抑制剂prexasertib的可操作节点
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p095
T. Teng, Stephen Paik, Shan-Chuan Zhao, Ashley H Choi, S. Lombardo, Shangtao Liu, Samuel R Meier, Yi Yu, Jannik N. Anderson, A. Huang, Fang Li, Xuewen Pan
{"title":"Abstract P095: Isogenic CRISPR anchor screens identified actionable nodes to CHK1/2 inhibitor prexasertib in TP53 mutant cancer","authors":"T. Teng, Stephen Paik, Shan-Chuan Zhao, Ashley H Choi, S. Lombardo, Shangtao Liu, Samuel R Meier, Yi Yu, Jannik N. Anderson, A. Huang, Fang Li, Xuewen Pan","doi":"10.1158/1535-7163.targ-21-p095","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p095","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78586176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions Zenocutuzumab是一种有效的HER2/HER3 Biclonics®抗体，用于NRG1融合的癌症
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p201
Jan Gerlach, I. Odintsov, R. Schackmann, M. Ladanyi, J. J. V. van Bueren, R. Somwar, C. Geuijen
{"title":"Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions","authors":"Jan Gerlach, I. Odintsov, R. Schackmann, M. Ladanyi, J. J. V. van Bueren, R. Somwar, C. Geuijen","doi":"10.1158/1535-7163.targ-21-p201","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p201","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75278879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas P044:蛋白精氨酸甲基转移酶5 (PRMT5)脑渗透抑制剂PRT811在晚期实体瘤(包括复发性高级别胶质瘤)患者中的一期剂量递增研究
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p044
G. Falchook, J. Glass, V. Monga, P. Giglio, D. Mauro, J. Viscusi, P. Scherle, N. Bhagwat, William Sun, R. Chiaverelli, Eric Mintah, L. Clements, T. Johanns, M. McKean
{"title":"Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas","authors":"G. Falchook, J. Glass, V. Monga, P. Giglio, D. Mauro, J. Viscusi, P. Scherle, N. Bhagwat, William Sun, R. Chiaverelli, Eric Mintah, L. Clements, T. Johanns, M. McKean","doi":"10.1158/1535-7163.targ-21-p044","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p044","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72697423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Abstract P210: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan P210: MDM2基因扩增作为MDM2抑制剂米拉德美坦的预测性生物标志物
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p210
V. Tirunagaru, M. Gounder, Prasanna Kumar, D. Hong, R. Doebele
{"title":"Abstract P210: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan","authors":"V. Tirunagaru, M. Gounder, Prasanna Kumar, D. Hong, R. Doebele","doi":"10.1158/1535-7163.targ-21-p210","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p210","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74573215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract P111: Therapeutic KRASG12C inhibition alleviates KRAS-driven immunosuppression 治疗性KRASG12C抑制可缓解kras驱动的免疫抑制
Poster Presentations - Proffered Abstracts Pub Date : 2021-12-01 DOI: 10.1158/1535-7163.targ-21-p111
E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. L. Sopena, P. East, M. M. Arcas, J. Downward
{"title":"Abstract P111: Therapeutic KRASG12C inhibition alleviates KRAS-driven immunosuppression","authors":"E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. L. Sopena, P. East, M. M. Arcas, J. Downward","doi":"10.1158/1535-7163.targ-21-p111","DOIUrl":"https://doi.org/10.1158/1535-7163.targ-21-p111","url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"138 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73311219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信